The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination

Neoplasia (United States)

Volumn 15, Issue 11, 2013, Pages 1251-1261

  Kogure, Masaharu ^a,b   Takawa, Masashi ^a   Saloura, Vassiliki ^c   Sone, Kenbun ^c   Piao, Lianhua ^c   Ueda, Koji ^d   Ibrahim, Reem ^a   Tsunoda, Tatsuhiko ^d   Sugiyama, Masanori ^b   Atomi, Yutaka ^b   Nakamura, Yusuke ^c   Hamamoto, Ryuji ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CHICAGO   (United States)

^d RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2B; HISTONE METHYLTRANSFERASE; MONOMETHYLATE LYSINE 120 ON HISTONE H2B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HISTONE UBIQUITINATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN PROCESSING; WESTERN BLOTTING;

CARCINOGENESIS; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HISTONES; HUMANS; LYSINE; MCF-7 CELLS; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION, GENETIC; UBIQUITINATION;

EID: 84888409855     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131436     Document Type: Article

References (50)

1. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al. (2011). Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102, 1298-1305.
2. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8, 890-896.
3. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III, Diaz E, et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112.
4. Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, and Nakatani Y (1999). Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J Biol Chem 274, 1189-1192.
5. Suka N, Suka Y, Carmen AA, Wu J, and Grunstein M (2001). Highly specific antibodies determine histone acetylation site usage in yeast heterochromatin and euchromatin. Mol Cell 8, 473-479.
6. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, Beeser A, Etkin LD, Chernoff J, Earnshaw WC, et al. (2003). Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113, 507-517.
7. Zhu B, Zheng Y, Pham AD, Mandal SS, Erdjument-Bromage H, Tempst P, and Reinberg D (2005). Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell 20, 601-611.
8. Nathan D, Ingvarsdottir K, Sterner DE, Bylebyl GR, Dokmanovic M, Dorsey JA, Whelan KA, Krsmanovic M, Lane WS, Meluh PB, et al. (2006). Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev 20, 966-976.
9. Sun ZW and Allis CD (2002). Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 418, 104-108.
10. Minsky N, Shema E, Field Y, Schuster M, Segal E, and Oren M (2008). Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol 10, 483-488.
11. Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD, Eick D, Aylon Y, Oren M, and Johnsen SA (2009). CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3′-end processing. EMBO Rep 10, 894-900.
12. Kim J, Hake SB, and Roeder RG (2005). The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Mol Cell 20, 759-770.
13. Fierz B, Chatterjee C, McGinty RK, Bar-Dagan M, Raleigh DP, and Muir TW (2011). Histone H2B ubiquitylation disrupts local and higher-order chromatin compaction. Nat Chem Biol 7, 113-119.
14. Fuchs G, Shema E, Vesterman R, Kotler E, Wolchinsky Z, Wilder S, Golomb L, Pribluda A, Zhang F, Haj-Yahya M, et al. (2012). RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation. Mol Cell 46, 662-673.
15. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, and Nakamura Y (2004). SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6, 731-740.
16. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, and Furukawa Y (2006). Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97, 113-118.
17. Cho HS, Shimazu T, Toyokawa G, Daigo Y, Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, et al. (2012). Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat Commun 3, 1072.
18. Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, Toyokawa G, Takawa M, Chen T, Kurash JK, et al. (2011). Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res 71, 655-660.
19. Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Maejima K, Ueda K, Masuda A, et al. (2012). Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res 72, 3217-3227.
20. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al. (2011). Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128, 574-586.
21. Kogure M, Takawa M, Cho HS, Toyokawa G, Hayashi K, Tsunoda T, Kobayashi T, Daigo Y, Sugiyama M, Atomi Y, et al. (2013). Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G1/S transition. Cancer Lett 336, 76-84.
22. Li H and Durbin R (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760.
23. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. (2008). Model-based analysis of ChIPSeq (MACS). Genome Biol 9, R137.
24. Feng J, Liu T, and Zhang Y (2011). Using MACS to identify peaks from ChIPSeq data. Curr Protoc Bioinformatics 34, 2.14.1-2.14.14. Chapter 2, Unit 2 14.
25. Kadota K, Nishiyama T, and Shimizu K (2012). A normalization strategy for comparing tag count data. Algorithms Mol Biol 7, 5.
26. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, et al. (2010). Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 9, 59.
27. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et al. (2011). Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 128, 562-573.
28. Pavri R, Zhu B, Li G, Trojer P, Mandal S, Shilatifard A, and Reinberg D (2006). Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 125, 703-717.
29. Moyal L, Lerenthal Y, Gana-Weisz M, Mass G, So S, Wang SY, Eppink B, Chung YM, Shalev G, Shema E, et al. (2011). Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. Mol Cell 41, 529-542.
30. Vitaliano-Prunier A, Babour A, Hérissant L, Apponi L, Margaritis T, Holstege FC, Corbett AH, Gwizdek C, and Dargemont C (2012). H2B ubiquitylation controls the formation of export-competent mRNP. Mol Cell 45, 132-139.
31. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL, and McMahon SB (2008). The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29, 102-111.
32. Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, et al. (2008). The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev 22, 2664-2676.
33. Shema E, Kim J, Roeder RG, and Oren M (2011). RNF20 inhibits TFIISfacilitated transcriptional elongation to suppress pro-oncogenic gene expression. Mol Cell 42, 477-488.
34. Chernikova SB, Razorenova OV, Higgins JP, Sishc BJ, Nicolau M, Dorth JA, Chernikova DA, Kwok S, Brooks JD, Bailey SM, et al. (2012). Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability. Cancer Res 72, 2111-2119.
35. Hahn MA, Dickson KA, Jackson S, Clarkson A, Gill AJ, and Marsh DJ (2012). The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Hum Mol Genet 21, 559-568.
36. Prenzel T, Begus-Nahrmann Y, Kramer F, Hennion M, Hsu C, Gorsler T, Hintermair C, Eick D, Kremmer E, Simons M, et al. (2011). Estrogendependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res 71, 5739-5753.
37. Leicher T, Roeper J, Weber K, Wang X, and Pongs O (1996). Structural and functional characterization of human potassium channel subunit β1 (KCNA1B). Neuropharmacology 35, 787-795.
38. Schultz D, Litt M, Smith L, Thayer M, and McCormack K (1996). Localization of two potassium channel β subunit genes, KCNA1B and KCNA2B. Genomics 31, 389-391.
39. Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, et al. (2004). RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA 101, 10833-10838.
40. Mancarelli MM, Zazzeroni F, Ciccocioppo L, Capece D, Po A, Murgo S, Di Camillo R, Rinaldi C, Ferretti E, Gulino A, et al. (2010). The tumor suppressor gene KCTD11REN is regulated by Sp1 and methylation and its expression is reduced in tumors. Mol Cancer 9, 172.
41. Birerdinc A, Nohelty E, Marakhonov A, Manyam G, Panov I, Coon S, Nikitin E, Skoblov M, Chandhoke V, and Baranova A (2010). Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region. Tumour Biol 31, 33-45.
42. Ivanov DV, Tyazhelova TV, Lemonnier L, Kononenko N, Pestova AA, Nikitin EA, Prevarskaya N, Skryma R, Panchin YV, Yankovsky NK, et al. (2003). A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3. FEBS Lett 539, 156-160.
43. Rybalchenko V, Prevarskaya N, Van Coppenolle F, Legrand G, Lemonnier L, Le Bourhis X, and Skryma R (2001). Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Mol Pharmacol 59, 1376-1387.
44. Lewis RS and Cahalan MD (1995). Potassium and calcium channels in lymphocytes. Annu Rev Immunol 13, 623-653.
45. Smith BC and Denu JM (2009). Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 1789, 45-57.
46. Murtagh JJ Jr, Eddy R, Shows TB, Moss J, and Vaughan M (1991). Different forms of Go alpha mRNA arise by alternative splicing of transcripts from a single gene on human chromosome 16. Mol Cell Biol 11, 1146-1155.
47. Garcia-Marcos M, Ghosh P, and Farquhar MG (2011). Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene 30, 2691-2696.
48. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873.
49. Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, et al. (2010). Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-κB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) 3, 424-437.
50. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Kim SS, Ahn CH, Yoo NJ, and Lee SH (2009). Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol 217, 702-706.